Itm Solucin Gmbh
Clinical trials sponsored by Itm Solucin Gmbh, explained in plain language.
-
New radiation therapy aims to slow aggressive gut and pancreatic tumors
Disease control OngoingThis study tests a targeted radiation treatment (PRRT with 177Lu-Edotreotide) against the best standard care for people with aggressive neuroendocrine tumors of the stomach, intestines, or pancreas. About 259 adults whose tumors have specific markers will be randomly assigned to …
Phase: PHASE3 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New radiation therapy shows promise against hard-to-treat gut and pancreas cancers
Disease control OngoingThis study tests a new type of radiation therapy (PRRT with 177Lu-Edotreotide) against a standard targeted drug (everolimus) in people with advanced neuroendocrine tumors that have spread and can't be removed by surgery. About 324 participants will be randomly assigned to one of …
Phase: PHASE3 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC